Curetis to Publish its Annual Results 2016 on April 12, 2017
(Thomson Reuters ONE) -
Curetis /
Curetis to Publish its Annual Results 2016 on April 12, 2017
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Curetis to Publish its Annual Results 2016 on April 12, 2017
- Company to host earnings conference call and webcast
Amsterdam, the Netherlands and Holzgerlingen, Germany, April 4, 2017 -- Curetis
N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of
next-level molecular diagnostic solutions, today announced that it will publish
its full-year 2016 financial results on April 12, 2017. In addition, the Company
will host a public earnings conference call and webcast on April 12, 2017, at
03:00 pm CET / 09:00am EST to present the financial results of 2016, highlight
the most important events and provide an outlook for 2017.
The conference call will be supplemented by a presentation which can be accessed
during the call at http://www.curetis.com/en/investors/financial-reports-and-
conferences.html.
For participating in the earnings call conference please access the presentation
at http://www.audio-webcast.com/ using the passcode curetis0417.
To access the call, please dial the following numbers using the passcode
93120684#
Belgium: +32 11500307
Germany: +49 69222229043
Netherlands: +31 107137273
UK: +44 2030092452
U.S.: +1 855 4027766
Further country-specific dial-in numbers can be found at
http://events.arkadin.com/ev/docs/International Access Numbers_
UKFELBRI1_SU7.pdf
The full annual financial report 2016 will be available as of April 12, 2017, at
http://www.curetis.com/en/investors/financial-reports-and-conferences.html
The live webcast and a replay will be available at http://curetis120417-
live.audio-webcast.com.
Disclaimer
CAUTION - Investigational device. Limited by Federal (or United States) law to
investigational use. The information contained in this communication does not
constitute nor imply an offer to sell or transfer any product, and no product
based on the Curetis Unyvero technology is currently available for sale in the
United States of America or Canada. The analytical and clinical performance
characteristics of any Curetis Unyvero product which may be sold at some future
point in time in the U.S. have not yet been established.
###
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the
development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis
enable rapid multi-parameter pathogen and antibiotic resistance marker detection
in only a few hours, a process that today can take up to days or even weeks with
other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and
Euronext Brussels and private equity funds of over EUR 63.5 million.
Furthermore, Curetis has entered into a debt financing facility with EIB for up
to EUR 25 million. The company is based in Holzgerlingen near Stuttgart,
Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies,
and has entered into several international distribution agreements covering many
countries across Europe, the Middle East and Asia.
For further information, please visit www.curetis.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.
The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information, future
events or for other reasons.
This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be identified
by the use of forward-looking terminology, including the terms "believes",
"estimates", "anticipates", "expects", "intends", "may", "will", or "should",
and include statements Curetis makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. Curetis' actual results may differ
materially from those predicted by the forward-looking statements. Curetis
undertakes no obligation to publicly update or revise forward-looking
statements, except as may be required by law.
Contact details
Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr(at)curetis.com or ir(at)curetis.com
www.curetis.com - www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(at)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth(at)theruthgroup.com
Tel. +1 646 536 7012
20160404_Curetis_PR_EN:
http://hugin.info/171382/R/2093418/791310.pdf
Curetis_Logo:
http://hugin.info/171382/R/2093418/791312.jpg
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Curetis via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 04.04.2017 - 08:30 Uhr
Sprache: Deutsch
News-ID 534219
Anzahl Zeichen: 6711
contact information:
Town:
Holzgerlingen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 154 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Curetis to Publish its Annual Results 2016 on April 12, 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Curetis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
